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In patients with non-seminomatous germ cell tumours (NSGCTs) who receive chemotherapy and have
residual disease, a persistently elevated serum marker level after induction chemotherapy indicates active
and progressive disease. High-dose chemotherapy (HDCT) is the standard treatment for patients with
relapsed NSGCT. We present a case of a patient with residual disease from NSGCT who showed an
increase in serum alpha-fetoprotein levels after HDCT, mimicking progression. Resection of the mass did
not show viable cells in the tumour specimen, thus suggesting that the elevated level of the marker was
expression of hepatic reconstitution after drug-induced liver damage. HDCT is increasingly used in cases
of relapsed NSGCT, and the possibility of treatment-induced alpha-fetoprotein elevation must be taken into
account in patient management.
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Introduction
Germ cell tumours are rare neoplasms accounting
for less than 1% of all malignancies and are most
frequently diagnosed in men in the third decade of
life.1 Mortality has declined markedly since cisplatin
was introduced as the basis of chemotherapy in the
mid-1970s.1 In the cisplatin era, the 10-year survival
rate of patients with metastatic non-seminomatous
germ cell tumours (NSGCTs) treated with this drug
increased significantly from 76% during the period
1977–1986 to 88% in the period 1987–1996.2 This
improvement resulted mainly from an increase in the
survival of patients with poor prognosis and indicates
more effective management of NSGCT over time.
High-dose chemotherapy (HDCT) with haematopoie-
tic progenitor cell support has led to an approxi-
mately 15% improvement in survival of these patients
compared to historical data.3–6Moreover, in cisplatin-
refractory disease, early tandem HDCT represents the
recommended option but is potentially curative in
only one-third of these patients.7 In NSGCT pa-
tients with poor prognosis who receive primary or sal-
vage chemotherapy and show residual disease with
negative serum alpha-fetoprotein (AFP) and beta-
human chorionic gonadotropin (beta-HCG), radical
resection of all residual lesions is mandatory.8,9 Per-
sistent elevation of serum tumour markers, especially
if levels begin to rise even further, is usually expression
of progressive disease that requires further chemo-
therapy, thus delaying surgery. We report the case of
an NSGCT patient showing liver toxicity and AFP
surge after HDCT to outline the possibility of liver
damage as the cause of increased AFP levels.
Case Report
A 25-year-old male was admitted to hospital with
severe chest pain and persistent cough. A chest-X-ray
revealed a large mass in the anterior mediastinum,
confirmed by CT scan (Fig. 1A). A biopsy was per-
formed and mediastinal NSGCT was diagnosed.
Histology was not further characterized due to the
paucity of bioptic material and necrotic areas. No
other sites of disease were detected at whole body CT
scan. Laboratory tests revealed elevated serum beta-
HCG (13 mUI/ml) and carcinoembryonic antigen
(15 mg/dl). The patient underwent induction che-
motherapy with cisplatin 20 mg/m2 and etoposide
100 mg/m2 administered on days 1–5, and bleomycin
30 IU on days 2, 9, and 16 (PEB), at 3-week intervals.
Marker negativization was observed after the first
course of PEB and a CT scan showed a radiological
partial remission after the third treatment course
(Fig. 1B). Four weeks after the end of PEB, the
patient received cisplatin 20 mg/m2 and etoposide
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100 mg/m2 on days 1–5 followed by granulocyte-
macrophage colony-stimulating factor 5 mg/kg/day to
mobilize peripheral blood progenitor cells. Fourteen
days after mobilization, 2.76106 CD34z cells/kg b.w.
were collected by a single leukapheresis and 4 weeks
later the patient received a single course of HDCTwith
carboplatin AUC 20, etoposide 1800 mg/m2 and
cyclophosphamide 6400 mg/m2 divided into four
doses given on days 1, 2, 3, and 4. Peripheral blood
progenitor cells were reinfused on day 7, followed
by granulocyte colony-stimulating factor 5 mg/kg/day
until haematopoietic reconstitution. Post-transplant
neutropenia,500/ml and thrombocytopenia,20 000/ml
lasted 9 and 7 days, respectively. Persistent grade-3
neutropenia was observed for the following 6 weeks.
Severe stomatitis was reported for 9 days. On the
seventh day after the start of HDCT, the patient showed
serum aspartate aminotransferase (AST) 923 U/l and
alanine aminotransferase (ALT) 909 U/l, progres-
sively reducing until normalization was reached at
z20 days. Although no change in tumour dimension
was observed in the CT scan performed 3 weeks after
HDCT (Fig. 1C), an increase in AFP (101 ng/ml) was
seen at z28 days. For these reasons, surgical resec-
tion of the residual mass was postponed. AFP levels
normalized after z106 days (Fig. 2) and surgical re-
section was performed shortly afterwards, the resected
residua consisting of fibrosis and necrosis. Five years
have passed since the induction chemotherapy and the
patient is still disease-free.
Discussion
In patients with poor prognosis NSGCT and post-
chemotherapy residual masses, surgical resection is
indicated only if serum AFP and beta-HCG levels are
within the normal range. A persistently elevated
serum marker level after induction chemotherapy is
suggestive of progressive disease and salvage therapy
is thus contraindicated.10 Conversely, a small num-
ber of studies reported that some patients with
persistently elevated serum tumour markers after
chemotherapy had locoregional disease and were
amenable to surgical resection.11,12 It thus appears
important to clarify which patients with high serum
tumour markers could benefit from surgical resec-
tion, although as yet no clear clinical or patholo-
gical variables have been found to identify such
candidates.
Vuky and co-workers11 reported their single-centre
experience of post-chemotherapy surgery in patients
with mediastinal NSGCT, highlighting the role of
surgery in patients with elevated serum tumour
markers. Of the 13 patients who had abnormally
elevated markers before surgical resection, three with
elevated AFP alone showed long-term survival. Re-
sected residual masses consisted of mature teratoma,
necrosis or viable malignant cells. Another study
retrospectively reviewed 18 patients with mediastinal
NSGCT who were selected for surgical resection in
spite of elevated tumour markers after chemother-
apy.12 In this series, only eight patients remained
disease-free; all had elevated AFP (median 70, range
26.6–830) but normal beta-HCG pre-resection, and all
Figure 1 Patient with mediastinal germ cell tumour with
alpha-fetoprotein elevation after high-dose chemotherapy.
(A) Chest CT scan upon hospital admission revealed a large
tumour mass in the anterior mediastinum. (B) After three
courses of induction chemotherapy, a chest CT scan showed
a substantial reduction in the tumour mass. (C) After high-
dose chemotherapy, chest CT scan showed no further
modification in tumour size.
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resected specimens showed necrosis or mature teratoma.
Small microscopic areas of tumour in residual masses
missed by the pathologist or slow tumour marker
decrease prior to resection were indicated as possible
explanations for the high AFP value. In both case
series, all but one of the patients with elevated
presurgical AFP (,1000 ng/ml) and without viable
malignant cells in bioptic specimens showed long-term
survival.
In our patient whose serum AFP levels were
continuously negative before and during treatment,
elevation of transaminases and AFP may have been
the expression of hepatic reconstitution after drug-
induced liver damage.13,14 In fact, most chemother-
apeutic drugs administered to patients with germ cell
tumours, e.g. cisplatin, etoposide, and cyclopho-
sphamide, can induce hepatotoxicity.14 When admi-
nistered at high doses, liver injury occurs in around
20–50% of cases.8
Post-chemotherapy resection notwithstanding ele-
vated AFP levels should only be considered in
NSGCT patients selected on the basis of their
clinical conditions, potential radical resectability,
and radiological situation. Serum AFP .1000 ng/ml
and its possible correlation with drug-induced liver
toxicity must therefore be taken into account in
each individual. Concanavalin A is a lectin that
permits the separation of AFP molecular variants
on the basis of their carbohydrate moiety. In a
prospective study by Mora and co-workers, the
concanavalin A affinity assay was used to discrimi-
nate between germinal or hepatic origin of AFP in
germ cell tumour patients during chemotherapy or
follow-up.15 This assay could thus help to distin-
guish between AFP produced by germ cell tumours
or by liver injury, including chemotherapy-induced
hepatic toxicity, and thus facilitate surgical decision
making.16
In conclusion, increased AFP levels in NSGCT
patients must be interpreted with caution when
post-chemotherapy liver damage is present. HDCT is
increasingly used in these patients and the possibility
of treatment-induced false-positive serum AFP eleva-
tion must be borne in mind. Strict monitoring of AST/
ALT and bilirubin levels after HDCT is recom-
mended to better evaluate any increase in AFP values.
In patients with AFP elevation after HDCT but no
clinical–radiological evidence of progression, resection
of residual masses can be considered.
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